Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase of over 15% compared to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 products across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 9327.94 million yuan, 6356.86 million yuan, 6713.05 million yuan, and 7775.27 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. Company Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium Enterprises" [3][28]. Competitive Advantages - The company has a well-established national sales network and a deep communication mechanism with hospitals and orthopedic doctors, enhancing product recognition and market penetration [5][35]. - Aide Technology has obtained 108 patents, with a research and development investment ratio of 6.96% from 2022 to 2024, indicating a strong commitment to innovation [5][35]. Market Trends - The demand for orthopedic implants is driven by a high prevalence of osteoporosis and vertebral compression fractures among the elderly population, with over 32% of individuals aged 65 and above affected [4][36]. - The company is adapting to the normalized procurement policies by promoting non-procurement products, which have shown steady growth, partially offsetting the revenue decline from procurement products [47]. Valuation Analysis - The company's projected price-to-earnings (PE) ratio for 2024 is 13.50, which is at a discount compared to comparable companies in the industry, whose average PE is 57.78 [25][26].

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase exceeding 15% relative to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 items across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 93.28 million yuan, 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. - The company's gross margin is expected to be 62.45%, 57.80%, 58.05%, and 58.90% from 2022 to 2025 [50]. Business Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium-sized Enterprises" [3][28]. Competitive Position - The company ranks third among domestic manufacturers of spinal vertebral body shaping systems and sixth among spinal implant manufacturers [3][28]. - Aide Technology has a well-established national sales network and a strong communication mechanism with hospitals and orthopedic surgeons, enhancing product recognition and market penetration [5][35]. Investment Analysis - The company is positioned to benefit from the ongoing trend of centralized procurement in the industry, which is expected to normalize pricing and enhance market opportunities [4][36]. - The company’s revenue from non-procurement products is growing, helping to offset declines in procurement product revenues [47]. Use of Proceeds - The company plans to use the proceeds from its public offering for expanding orthopedic consumables production, building a research center, and enhancing its marketing network [53][54].

Group 1: Company Overview - Yisiwei is a leading domestic company in automotive manufacturing machine vision equipment, holding the largest market share in China [2] - Aide Technology specializes in orthopedic consumables, focusing on the research, production, and sales of medical devices [3] Group 2: Financial Performance - Yisiwei's projected revenues for 2022 to 2024 are 223 million, 355 million, and 392 million yuan, with net profits of 6 million, 61 million, and 86 million yuan respectively [2] - Aide Technology's projected revenues from 2022 to 2025 are 286 million, 262 million, 275 million, and 302 million yuan, with net profits of 93 million, 64 million, 67 million, and 78 million yuan respectively [3] Group 3: Market Position and Growth Potential - Yisiwei's products are widely used by mainstream joint ventures, domestic new forces, and well-known automotive parts companies, indicating strong market penetration [2] - Aide Technology ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, showcasing its competitive position [3] Group 4: Upcoming IPO Details - Yisiwei's IPO price is set at 55.95 yuan per share with a price-to-earnings ratio of 90.39, while Aide Technology's IPO price is 7.67 yuan per share with a price-to-earnings ratio of 14.98 [1][3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 26.68 CNY, based on a 46 times PE valuation for 2025 [4][7]. Core Views - The company is expected to experience a turning point in performance as the impact of centralized procurement diminishes, with a projected revenue increase of 33.9% in 2025 [12]. - The company achieved a revenue of 4.9 billion CNY in the first half of 2025, representing a year-on-year growth of 28.3%, and a net profit of 1.1 billion CNY, up 44.9% year-on-year [12]. - The company is actively expanding its international market presence, with significant progress in obtaining CE and FDA approvals for its products, indicating strong international competitiveness [12]. Financial Summary - Revenue projections for 2025-2027 are 1,079 million CNY, 1,306 million CNY, and 1,578 million CNY, respectively, with corresponding growth rates of 33.9%, 21.0%, and 20.9% [6]. - The company's net profit for 2025 is forecasted at 224 million CNY, with a year-on-year growth of 79.4% [6]. - The gross margin is expected to stabilize around 67.5% in 2025, with a net margin of 20.8% [6].